# US 8,772,479 B2 · Oligomer-containing substituted aromatic triazine compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,772,479 B2
- Document ID: US8772479B2
- Status: Granted
- Kind: B2
- Application number: 13/319,824
- Filed: 2010-05-13
- Published: 2012-05-17
- Granted: 2014-07-08
- Earliest claimed: 2009-05-13
- Assignees: Nektar Therapeutics
- Applicants: Jennifer Riggs-Sauthier; Bo-Liang Deng
- Inventors: Jennifer Riggs-Sauthier; Bo-Liang Deng
- Web page: https://patentgrep.com/patent/US8772479B2

## CPC

- C07D 253/075: Two hetero atoms, in positions 3 and 5
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 35/00: Antineoplastic agents
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to (among other things) oligomer-containing substituted aromatic triazine compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.

## Claims

### Claim 1

A compound of the structure
wherein n is an integer selected from the group consisting of 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11, and pharmaceutically acceptable salts thereof.

### Claim 2

A composition comprising a compound of the structure
wherein n is an integer selected from the group consisting of 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11, and pharmaceutically acceptable salts thereof, and
a pharmaceutically acceptable excipient.

### Claim 3

A dosage form comprising a compound of the structure
wherein n is an integer selected from the group consisting of 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11, and pharmaceutically acceptable salts thereof.

### Claim 4 (depends on 1)

The compound of claim 1, wherein n is 2.

### Claim 5 (depends on 1)

The compound of claim 1, wherein n is 3.

### Claim 6 (depends on 1)

The compound of claim 1, wherein n is 4.

### Claim 7 (depends on 1)

The compound of claim 1, wherein n is 5.

### Claim 8 (depends on 1)

The compound of claim 1, wherein n is 6.

### Claim 9 (depends on 1)

The compound of claim 1, wherein n is 7.

### Claim 10 (depends on 1)

The compound of claim 1, wherein n is 8.

### Claim 11 (depends on 1)

The compound of claim 1, wherein n is 9.

### Claim 12 (depends on 1)

The compound of claim 1, wherein n is 10.

### Claim 13 (depends on 1)

The compound of claim 1, wherein n is 11.